Forma Therapeutics (FMTX) Stock Price, News & Analysis

Company Overview

Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing Olutasidenib, a selective inhibitor for cancers with isocitrate dehydrogenase 1 gene mutations, which is in Phase II trial for the treatment of relapsed/refractory acute myeloid leukemia and Phase I trial to treat glioma; and FT-8225, a liver-targeted fatty-acid synthase inhibitor designed to block de novo lipogenesis in the liver. Forma Therapeutics Holdings, Inc. was founded in 2007 and is headquartered in Watertown, Massachusetts. As of October 14, 2022, Forma Therapeutics Holdings, Inc. operates as a subsidiary of Novo Nordisk A/S.

Key Stats

• Today's Range: $20.01 to $20.01
• 50-Day Range: $19.91 to $20.01
• 52-Week Range: $4.95 to $20.68
• Volume: 1 shs
• Average Volume: 847,595 shs
• Market Capitalization: $957.54 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

FMTX Stock Analysis - Frequently Asked Questions

How were Forma Therapeutics' earnings last quarter?

Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX) announced its quarterly earnings results on Friday, November, 12th. The company reported ($0.91) EPS for the quarter, topping the consensus estimate of ($0.96) by $0.05.

When did Forma Therapeutics IPO?

Forma Therapeutics (FMTX) raised $201 million in an initial public offering on Friday, June 19th 2020. The company issued 11,800,000 shares at a price of $16.00-$18.00 per share. Jefferies' SVB Leerink and Credit Suisse acted as the underwriters for the IPO.

What other stocks do shareholders of Forma Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Forma Therapeutics investors own include Tesla (TSLA), HubSpot (HUBS), Cheniere Energy (LNG), Netflix (NFLX), Marvell Technology (MRVL) and Viper Energy (VNOM).

Company Calendar

• Last Earnings: 11/12/2021
• Today: 5/29/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: N/A
• Current Symbol: NASDAQ:FMTX
• CIK: 1538927
• Web: www.formatherapeutics.com
• Phone: 617-679-1970
• Fax: N/A
• Employees: 166
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($4.00)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$172.96 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -39.68%
• Return on Assets: -35.33%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 12.74
• Quick Ratio: 12.74

Sales & Book Value

• Annual Sales: $100.56 million
• Price / Sales: 9.52
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $10.51 per share
• Price / Book: 1.90

Miscellaneous

• Outstanding Shares: 47,853,000
• Free Float: 45,082,000
• Market Cap: $957.54 million
• Optionable: Not Optionable
• Beta: -0.94